Skip to content

Erasca, Inc. ERAS Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Eli Lilly logo
Eli LillyLLY
Pfizer logo
PfizerPFE
Amgen logo
AmgenAMGN
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
Tango Therapeutics logo
Tango TherapeuticsTNGX

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s software and technology licenses, net?
Erasca, Inc. (ERAS) reported software and technology licenses, net of $1.45M in Q1 2026.
How has Erasca, Inc.'s software and technology licenses, net changed year-over-year?
Erasca, Inc.'s software and technology licenses, net decreased by 44.7% year-over-year, from $2.62M to $1.45M.
What is the long-term trend for Erasca, Inc.'s software and technology licenses, net?
Over 5 years (2020 to 2025), Erasca, Inc.'s software and technology licenses, net has grown at a 26.4% compound annual growth rate (CAGR), from $451K to $1.45M.